Lung cancer is the leading cause of cancer death worldwide, with metastasis underlying majority of related deaths. Angiomotin (AMOT), a scaffold protein, has been shown to interact with oncogenic Yes-associated protein/transcriptional co-activator with a PDZ-binding motif (YAP/TAZ) proteins, suggesting a potential role in tumor progression. However, the functional role of AMOT in lung cancer remains unknown. This study aimed to identify the patho-physiological characteristics of AMOT in lung cancer progression. Results revealed that AMOT expression was significantly decreased in clinical lung cancer specimens. Knockdown of AMOT in a low metastatic CL1-0 lung cancer cell line initiated cancer proliferation, migration, invasion and epithelial-mesenchymal transition. The trigger of cancer progression caused by AMOT loss was transduced by decreased cytoplasmic sequestration and increased nuclear translocation of oncogenic co-activators YAP/TAZ, leading to increased expression of the growth factor, Cyr61. Tumor promotion by AMOT knockdown was reversed when YAP/TAZ or Cyr61 was absent. Further, AMOT knockdown increased the growth and spread of Lewis lung carcinoma in vivo. These findings suggest that AMOT is a crucial suppressor of lung cancer metastasis and highlight its critical role as a tumor suppressor and its potential as a prognostic biomarker and therapeutic target for lung cancer.
INTRODUCTION
Lung cancer, particularly non-small cell lung cancer, is the leading cause of cancer-related deaths worldwide. 1, 2 The vast majority of deaths occur because patients are diagnosed in the advanced stage but even those with the early stages have high rates of relapse after effective therapy. 3, 4 Moreover, up to 40% of patients develop local or distal metastasis, resulting in dramatically increased mortality rates. 5 Thus understanding the processes that contribute to cancer progression, including cancer growth and metastasis, is crucial for developing effective therapeutic strategies and improving the cure rate.
Angiomotin (AMOT) was first identified as an angiostatinbinding protein that enhanced endothelial cell motility by reducing tight junctions and altering actin dynamics. [6] [7] [8] The AMOT family of proteins has three members: AMOT (p80 and p130 isoforms), AMOT-like protein 1 (AMOTL1) and AMOTL2. 9 The AMOTL1 and AMOTL2 genes also generate two splicing isoforms in humans. 9 AMOT has been shown to block the activity of Rich1, a small GTPase activating protein, leading to increased Rac1-GTP levels and altering growth signaling, tight junction and cell migration. 10, 11 AMOT p80 has been shown to promote cell growth by increasing mitogen-activated protein kinase activation in breast cancer. 12 In contrast to the stimulatory role of AMOT on cell growth, AMOT p130 decreased cell proliferation in breast cancer MDA-MB-468 cells in a recent study. 13 However, the functional role of AMOT in the development of lung cancer is poorly understood.
Yes-associated protein (YAP) and its paralogue, transcriptional co-activator with a PDZ-binding motif (TAZ), are transcription co-activators and major downstream targets regulated by the Hippo pathway. [14] [15] [16] [17] Sustained or elevated YAP/TAZ expression levels has been noted in human breast cancer and lung cancer cell lines. 14, 18, 19 The major regulatory control of YAP/TAZ activity is via alterations in their subcellular distribution and stability. The relationship between AMOT and YAP/TAZ is controversial: AMOT p130 can prevent the inactivating phosphorylation of YAP, resulting in the promotion of cell growth and tumorigenesis in liver cells, 20 whereas AMOT can regulate the Hippo pathway by sequestrating YAP/TAZ in the cytoplasm and increasing the actitvity of tumor-suppressor LATS1/2. 12, 13, [21] [22] [23] However, the role of AMOT in lung cancer is still poorly understood. This study was designed to identify the patho-physiological characteristics of AMOT in lung cancer progression.
RESULTS
Reduced AMOT (p130) expression in highly proliferative and invasive lung cancer cells in mouse and human lung cancer cell lines To investigate the candidate genes involved in lung cancer metastasis in vivo, Lewis lung carcinoma (LLC) cells were repeatedly transplanted into mice by tail vein injection, thereby creating the LLC-1, LLC-2, LLC-3, LLC-4 and LLC-5 cell line series. Because our previous study demonstrated that migratory ability was enhanced by increasing the time of transplantations (LLC-54LLC-44LLC-34LLC-24LLC-1), 24 the proliferative capacity of these cell strains were assessed. The cell proliferative ability of the LLC cells was significantly enhanced after a series of five transplantations (relative change to LLC-1 was 128.67 ± 9.90% and 186.69 ± 8.99% for LLC-3 and LLC-5, respectively) (Supplementary Figure S1A ). The invasiveness of LLC cells was also significantly enhanced by repeated transplantation (relative change to LLC-1 was 198.40 ± 13.27% and 238.75 ± 27.80% for LLC-3 and LLC-5, respectively) (Supplementary Figure S1B ), suggesting that the LLC-1/LLC-5 isogenic cell lines were useful for the study of cancer progression.
To investigate which candidate genes contributed to cancer progression, the RNA transcription profiles of LLC-1 and LLC-5 was assessed by microarray. The transcript levels of AMOT was 11.78fold higher in LLC-1 cells than in LLC-5 cells (Supplementary Figure  S2A) . The AMOT transcription level, as measured by quantitative real-time PCR (qRT-PCR), was significantly reduced in LLC-3 and LLC-5 cells (by 0.15 ± 0.04 and 0.04 ± 0.02-fold, respectively, P o0.05), compared with that in LLC-1 (Supplementary Figure  S2B ). The expression of AMOT was also negatively associated with the time of transplantations. Immunoblot analysis revealed that AMOT p130 protein levels were lower in LLC-5 cells than in LLC-1 and LLC-3 cells ( Figure 1a ).
To further assess the association between reduced AMOT levels and malignant cellular properties, AMOT levels were compared between the paired isogenic lung cancer cell lines CL1-0 (low invasiveness) and CL1-5 (high invasiveness). 25, 26 The level of AMOT mRNA was 3.44-fold higher in CL1-0 cells than in CL1-5 cells (Figure 1b ). Immunoblot analysis also revealed higher levels of AMOT p130 (118 kDa) in CL1-0 cells, consistent with the results of qRT-PCR. Notably, the AMOT p80 isoform (72 kDa) was undetectable in both CL1-0 and CL1-5 cells (Figure 1a ).
Reduced AMOT expression and elevated YAP in the nuclei of lung cancer cells Analysis of AMOT mRNA transcript from a lung cancer cDNA array was confirmatory for the pathogenic role of AMOT downregulation. The levels of AMOT mRNA transcript was significantly lower in the human tumor sections than in the non-tumor sections in 11 of the 24 (45.8%) of human lung cancer patients. Of the 11 low mRNA transcript samples, four had undetectable AMOT mRNA transcripts by q-PCR in tumor sections but was detected in the corresponding normal region. Nine of the 24 samples (37.5%) demonstrated no marked difference between tumor sections and matched non-tumor sections ( Supplementary Table S1 ).
The negative association of AMOT with nuclear YAP/TAZ was noted in clinical lung patient specimens (n = 15). Compared with the normal regions, AMOT levels were decreased in the cancer regions, with high YAP/TAZ levels, in the nuclei of lung cancer cells ( Figure 1c ). The AMOT and YAP/TAZ levels were also assessed by quantitative immunofluorescence and the results revealed that the amount of AMOT in the tumor regions were significantly reduced (389.73 × 10 4 ± 209.51 × 10 4 and 269.26 × 10 4 ± 125.94 × 10 4 for normal and tumor regions, respectively, P = 0.047). In addition, the level of nuclear YAP/TAZ proteins was increased (5.86 × 10 4 ± 10.92 × 10 4 and 56.53 × 10 4 ± 28.84 × 10 4 for normal and tumor regions, respectively, P = 0.0002) ( Figure 1d ). Cytosolic AMOT protein significantly but negatively correlated with the nuclear YAP/TAZ level (r = 0.69) in tumor region ( Figure 1e ).
Knockdown of AMOT increased cell proliferation, migration, invasion and mesenchymal protein expression
To investigate whether decreased AMOT expression was associated with lung adenocarcinoma cell progression, AMOT expression was reduced by shRNA transfection in CL1-0 cells. The AMOT shRNA transfection showed 498% inhibition of AMOT mRNA transcript (Supplementary Figure S3A ), while AMOT (p130) protein expression was completely inhibited in all stable clones (Supplementary Figure S3B ). Knockdown of AMOT significantly increased CL1-0 cell proliferation, as determined by bromodeoxyuridine (BrdU) incorporation (relative change to control shRNA plasmid-transfected CL1-0 cells: 211.78 ± 18.27% and 190.72 ± 23.40% for clones 17 and 18, respectively, P o 0.001) and WST-1 assays (relative change to control shRNA plasmidtransfected CL1-0 cells: 192.56 ± 32.60% and 180.86 ± 21.20% for clones 17 and 18, respectively, Po 0.001) (Figure 2a ; Supplementary Figure S3C ).
Scratch wound-healing assay analysis showed that knockdown of AMOT remarkably increased the migratory ability of CL1-0 cells (Supplementary Figure S3D ). Trans-well migration assay indicated that the inhibition of AMOT significantly increased cell motility (194.88 ± 16.40% and 189.78 ± 8.04% for stable clones 17 and 18, respectively, P o0.001), as compared with CL1-0 cells transfected with the control shRNA plasmid (Figure 2b) . Similarly, invasion assay revealed that AMOT-knockdown cells exhibited significantly higher invasiveness than control cells (218.89 ± 27.47% and 208.54 ± 24.12% for stable clones 17 and 18, respectively, P o0.001) ( Figure 2c ).
Because epithelial-mesenchymal transition (EMT) was important for cancer cells to metastasize, 27,28 the role of AMOT in EMT was assessed. The inhibition of AMOT by shRNA changed CL1-0 from a cobblestone-like cell morphology to a spindle-like fibroblastic morphology (Supplementary Figure S3E ). In addition, knockdown of AMOT expression decreased epithelial marker E-cadherin and increased mesenchymal markers such as N-cadherin and vimentin in the CL1-0 cells (Figure 2d ), suggesting that AMOT was involved in the regulation of EMT. Furthermore, AMOT inhibition increased the level of snail, a critical regulator of EMT, in the nuclear fraction of CL1-0 cells (Figure 2d ).
To further validate the role of AMOT p130 in cancer proliferation and migration, AMOT p130 expression was inhibited by shRNA transfection at different concentrations (3, 6 and 9 μg AMOT shRNA plasmid/6 cm dish). The AMOT shRNA plasmid significantly inhibited the level of AMOT protein in a dose-dependent manner in CL1-0 (Supplementary Figure S4A ). The silencing of AMOT also significantly enhanced cell proliferation, migration and EMT in a dose-dependent manner ( Supplementary Figures S4B and D) , which were consistent with the results of AMOT-knockdown stable clones.
Ectopic AMOT (p130) expression decreased cell proliferation and migration and restored epithelial protein expression To further investigate the role of AMOT, CL1-5 cells were transfected with AMOT (p130) cDNA. Immunoblot analysis reveals that AMOT (p130) was expressed in CL1-5 cells (Figure 3a ). Overexpression of AMOT significantly decreased CL1-5 cell proliferation (relative change to control pCMV plasmidtransfected CL1-5 cells: 70.86 ± 3.87% and 68.78 ± 14.19% for clones 4 and 8, respectively, P o0.01) ( Figure 3b ). In addition, the migration of AMOT-overexpressing CL1-5 cells was significantly suppressed compared with the control cells ( Figure 3c ).
Cells with enhanced AMOT expression exhibited significantly lower invasiveness compared with the control cells (74.97 ± 3.70% and 61.34 ± 8.26% for stable clones 4 and 8, respectively, P o0.001) ( Figure 3d ). Ectopic expression of AMOT changed CL1-5 from spindle-like fibroblastic morphology to a cobblestonelike cell phenotype (Supplementary Figure S5A ). The expression levels of epithelial protein E-cadherin and mesenchymal markers (N-cadherin, vimentin and snail) were significantly increased and decreased, respectively, in AMOT-overexpressing cells (Figure 3e ). Furthermore, the ectopic expression of AMOT decreased cell proliferation, migration and N-cadherin but increased E-cadherin expression in a dose-dependent manner ( Supplementary Figures S5B-E ).
AMOT decreased the nuclear location of YAP/TAZ by sequestering them in the cytoplasm Because previous studies reported that the AMOT protein could bind to the YAP and TAZ proteins, thereby inhibiting their oncogenic potential, 23 the interaction of AMOT with YAP and TAZ was investigated. With more times of transplantation of LLC cells (form LLC-1, LLC-3 to LLC-5), the cytosolic YAP/TAZ level decreased and the nuclear YAP/TAZ level increased progressively ( Figure 4a ). The cytoplasmic association of AMOT with YAP/TAZ was also remarkably higher in LLC-1 cells than in LLC-5 cells (Figure 4a ). Similarly, the YAP/TAZ level in the nuclei was higher in CL1-5 cells than in CL1-0 cells, and the cytoplasmic interaction of AMOT with YAP/TAZ was higher in CL1-0 cells than in CL1-5 cells (Figure 4b ).
Knockdown of AMOT by shRNA transfection increased the nuclear localization of YAP/TAZ in CL1-0 cells (Figure 4c ). On the other hand, overexpression of AMOT decreased the amount of YAP/ TAZ in the nuclei of CL1-5 cells (Figure 4c ). The inhibition of AMOT also decreased AMOT/YAP/TAZ association in CL1-0 cells, whereas enhanced AMOT level increased AMOT/YAP/TAZ interaction in CL1-5 cells (Figure 4c ). The role of YAP and TAZ was also confirmed by specific siRNA transfection. We transfected AMOT-knockdown CL1-0 with control siRNA, YAP, TAZ or both siRNA and checked that the transfections inhibited the targets specifically ( Supplementary  Figures S6A and B) . Silencing YAP or TAZ resulted in a partial reversion of cell proliferation and migration, while inhibition of both YAP and TAZ exhibited a complete restoration in AMOT-knockdown CL1-0 cells (Figure 4d ). Mesenchymal markers in AMOT-knockdown CL1-0 cells had similar results ( Figure 4e ). Cell lysates were immunoprecipitated with anti-YAP or TAZ antibody, and the co-immunoprecipitated AMOT was detected by immunoblotting with anti-AMOT antibody. AMOT-knockdown CL1-0 cells were transfected with either non-target, YAP or TAZ siRNA (10 nM). After 48 h transfection, the cell biological behaviors were evaluated. The knockdown efficiency of specific siRNA was determined by qRT-PCR, while cell proliferation was determined by BrdU assay. Cell migration was analyzed as previously described. # Denotes statistically significant difference from control siRNA-transfected cells, by Student's t-test (Po 0.05). All experiments were performed independently at least three times.
Involvement of YAP and TAZ on cell proliferation, migration and invasion
Because the major function of YAP/TAZ was transcription coactivation to stimulate gene expression and connective tissue growth factor (CTGF), Cyr61, BICR2 and ANKRD1 were wellcharacterized YAP target genes, 29, 30 this study assessed whether YAP and TAZ increased the expression of these genes in the LLC cell line series. The levels of Cyr61, ANKRD1 and BICR2 mRNA transcripts were 9.8-, 4.1-and 2.3-fold higher, respectively, in LLC-5 than in LLC-1 cells (Figure 5a ). Transfection of YAP or TAZ siRNA decreased YAP or TAZ mRNA transcript by 466% in LLC-5 (Supplementary Figure S7) . Knockdown of YAP expression in the LLC-5 cells significantly decreased the levels of Cyr61, ANKRD1 and BICR2 mRNA transcripts by 72.7, 54.3 and 65.4%, respectively, while the inhibition of TAZ by siRNA significantly reduced the levels of Cyr61, ANKRD1 and BICR2 mRNA transcripts by 60.9, 61.8 and 76.1%, respectively, in LLC-5 (Figure 5b) .
To further investigate whether Cyr61 act as downstream of AMOT, the role of AMOT, LLC-1 cells were transfected with AMOT shRNA plasmid. Transfection of AMOT shRNA decreased AMOT mRNA transcript by 490% in LLC-1 (Supplementary Figure S8A) . Inhibiting AMOT in LLC-1 cells increased the levels of Cyr61, ANKRD1 and BICR2 mRNA transcripts (10.77-, 4.02-and 2.38-fold, respectively, in clone 1 and 9.17-, 4.01-and 2.71-fold, respectively, in clone 2; Po 0.001) (Figure 5c ). Knockdown of AMOT increased the level of Cyr61 mRNA transcript in human lung cancer CL1-0 cells, whereas AMOT overexpression decreased it in CL1-5 cells ( Supplementary Figures S8B and C) . However, the level of YAP/ TAZ-inducible gene CTGF was not dependent on YAP/TAZ in lung cancer (data not shown).
To validate the regulatory role of YAP and TAZ on Cyr61 expression, YAP, TAZ or both were inhibited in AMOT-knockdown LLC-1 cells. Inhibition of YAP or TAZ alone partially decreased Cyr61 mRNA trascripts while silencing both YAP and TAZ completely eliminated Cyr61 enhancement, suggesting that both YAP and TAZ had critical modulating roles on Cyr61 expression ( Figure 5d ).
The role of YAP/TAZ was also assessed by siRNA knockdown in LLC-5 and CL1-5 cells. Transfection of YAP or TAZ siRNA decreased YAP or TAZ mRNA transcript by 465% in both LLC-5 and CL1-5 ( Supplementary Figure S7 and S9A ). Knockdown of YAP or TAZ significantly decreased the proliferation and migration of LLC-5 and CL1-5 cells ( Supplementary Figures S9B and C) while the inhibition of YAP and TAZ increased E-cadherin expression and decreased N-cadherin expression in CL1-5 and LLC-5 cells (Supplementary Figure S9D) . AMOT-knockdown LLC1 cells were transfected with either non-target, YAP, TAZ or YAP plus TAZ siRNA (10 nM) for 48 h. The Cyr61 mRNA transcript levels were then determined by qRT-PCR. LLC1 cells were transfected with control shRNA or AMOT shRNA plasmid, and the stable clones were established by puromycin selection. The relative mRNA levels of Cyr61, ANKRD1 and BICR2 in LLC1 and LLC5 were assessed by microarray. *Significant difference with the controls, by Student's t-test (Po 0.05). # Denotes statistically significant difference between control siRNA-transfected cells (P o0.05). All experiments were performed independently at least three times. Cyr61 contributed to cell proliferation, migration and EMT in AMOT-knockdown lung cancer We assessed whether Cyr61 was involved in lung cancer progression. Transfection of Cyr61 siRNA decreased Cyr61 mRNA transcript by 487% in AMOT-knockdown LLC-1 cells. This genetic inhibition did not affect the CTGF mRNA transcript (Supplementary Figure S10 ). Inhibition of Cyr61 significantly decreased the proliferation and migration of AMOT-knockdown LLC-1 (Figures 6a and b) . Moreover, blocking Cyr61 also increased E-cadherin expression and decreased N-cadherin expression in AMOT-knockdown LLC-1 (Figure 6c ).
Assessing the mechanism of Cy61 on cell proliferation and migration, the inhibition of AMOT increased the phosphorylation of focal adhesion kinase (FAK; Tyr397) and AKT, which were reduced by Cyr61 siRNA transfection (Figure 6d ). Both FAK and AKT inhibitors decreased cell migration in AMOT-knockdown LLC-1, suggesting that FAK/AKT might be involved in cell migration induced by AMOT knockdown (Figure 6e ).
Knockdown of AMOT increased lung cancer growth and metastasis in vivo
To assess the tumor growth of human lung cancer cells in a nude mice model, AMOT-knockdown CL1-0 cells was delivered by subcutaneous injection into the flanks of mice. The rate of tumor growth of AMOT-knockdown CL1-0 was enhanced compared with that of the control plasmid-transfected CL1-0 cells (Figure 7a ). This was consistent with the results of the in vitro data.
To further validate the regulation of AMOT on cell proliferation, AMOT-knockdown LLC was delivered by subcutaneous injection into the flanks of mice. Before AMOT-knockdown LLC1 transplantation, this study assessed whether AMOT silencing increased the ability of LLC in cell proliferation, migration and EMT. Inhibition of AMOT increased the cell proliferation, migration and EMT (with E-cadherin downregulation and N-cadherin upregulation) (Supplementary Figures S11A-C). These data were consistent with human lung cancer data. The rate of tumor growth of AMOT-knockdown LLC increased significantly, as compared with that of the control LLC in vivo (Figure 7b ).
To further test whether AMOT acted as a suppressor of lung cancer metastasis in vivo, LLC and AMOT-knockdown LLC cells were injected into the tail veins of mice. The mice were killed 24 days after, and the metastatic tumor nodules that formed in the lungs were examined. Knockdown of AMOT increased lung metastasis (tumor nodules, AMOT-knockdown clone 1: 138.33 ± 39.34; clone 2: 136.50 ± 14.97; control: 97.00 ± 21.07; Po 0.05; Figure 7c ).
Analysis of proliferation by Ki-67 immunohistochemical staining showed that the level of nuclear Ki-67 increased by 2.83-and 1.87fold in the tumors of AMOT-knockdown clone 1 and clone 2 LLC-1 cells in mice, respectively, as compared with the tumors of control plasmid-transfected LLC cells. Furthermore, YAP/TAZ were located in the cytosol of the tumors of control plasmid-transfected LLC cells, whereas they were prominently located in the nuclear fraction of the tumors of AMOT-knockdown clones 1 and 2 LLC-1 cells (Figures 7d and e ).
DISCUSSION
Lung cancer has been one of the most common causes of death worldwide for several decades. 1,2 A series of in vitro and in vivo investigations have assessed the role of AMOT in the regulation of lung cancer cell proliferation, migration and invasion, and the results clearly show that AMOT functions as a scaffold protein in modulating the oncogenic potential of YAP/TAZ and its target Cyr61 signaling by restricting its activity in lung cancer.
The role of AMOT in cancer is controversial. Yi et al. 20 report that AMOT acts as a YAP co-factor, augmenting its activity towards a specific set of genes that facilitate tumorigenesis in the liver by preventing its phosphorylation. The DNA vaccination targeting AMOT are reported to decrease tumor angiogenesis, resulting in cancer growth suppression. 31, 32 However, recent studies indicate that phosphorylated AMOT caused by tumor-suppressor LATS1/2 kinases restricts YAP-mediated gene response and cell growth. 13 Moreover, different isoforms of AMOT have been shown to exhibit different functions on cell migration: AMOT p80 increases cell migration, whereas AMOT p130 binds to and stabilizes tight junction ZO-1, which is an important marker of the epithelial phenotype. 33, 34 In this study, the knockdown of AMOT p130 increases the properties of lung cancer progression, including proliferation, migration, invasion and EMT. The inhibition of AMOT p130 expression also increases lung cancer metastasis in vivo, and a significant loss of AMOT p130 is observed in tumor regions in clinical lung cancer samples, further supporting that AMOT p130 may act as a tumor suppressor in lung cancer. Future studies investigating whether the expression pattern and modification of AMOT and isoforms influence their function in different types of tissue are warranted to elucidate the mechanisms of tumor repression by AMOT.
Increasing evidences demonstrate that YAP/TAZ are oncogenes in mammalian cells. 35, 36 YAP/TAZ genes have been reported to be overexpressed at a high frequency in various human cancers and are associated with poor prognosis. 36 Furthermore, YAP overexpression has been associated with non-small cell lung cancer, especially lung adenocarcinoma. 37, 38 Elevated YAP/TAZ levels are reported to induce target gene expression, resulting in cell proliferation, evasion of apoptosis and amplification of progenitor or stem cells, thereby promoting organ size. 39, 40 YAP/TAZ have also been reported to facilitate the processes of cancer metastasis, including inducing the loss of cell contact inhibition, migration, invasion and EMT. 41, 42 The activity of YAP/TAZ is regulated by physical interactions with other proteins such as AMOT, 23, 43, 44 which sequesters YAP/TAZ in the cytoplasm and inactivates it. In the present study, a loss of AMOT in cells leads to the accumulation of nuclear YAP/TAZ, because AMOT sequesters them in the cytoplasm. The knockdown of YAP/TAZ also prevents cancer cell proliferation, migration and EMT caused by the loss of AMOT, suggesting that YAP/TAZ has a critical role as an oncogenic promoter in lung cancer.
Cyr61 (also known as CCN1) is a secretory extracellular matrixassociated molecule of the matricellular CCN family. It is a multifunctional protein that has an important role in regulating cellular activities, such as cell attachment, migration, survival, growth, angiogenesis and gene expression. 45 Dysregulation of Cyr61 expression is associated with various types of tumors, including lung cancer. 45, 46 Blocking Cyr61 by neutralizing antibodies can decrease the cancer growth and metastasis in mice. 47 Cyr61 has also been shown to be a downstream target of YAP/TAZ and is involved in cancer growth, migration and metastasis owing to the dysregulation of Hippo signaling in lung cancer, ovarian cancer cells and breast cancer. 48 In this study, knockdown of AMOT increases Cyr61 expression. In contrast, YAP/TAZ inhibition decreases the transcription of Cyr61. Inhibition of Cyr61 by siRNA transfection prevents cancer progression mediated by AMOT knockdown, suggesting that AMOT can inhibit YAP/TAZ transcriptional activation and decrease Cyr61-mediated cancer progression in lung cancer.
Cyr61 has been reported to regulate cell proliferation and migration by directly binding with integrin ανβ3 and ανβ5. 49 Interaction of Cyr61 with integrin increases FAK phosphorylation, which enhances AKT activation. 50 AKT has been a critical mediator of cell proliferation, survival and metastasis in a variety of cell types. 51 Results of the present study show that AMOT downregulation increases FAK and AKT phosphorylation, which are inhibited by Cyr61 silencing. Inhibition of AKT or FAK reduces the influence of AMOT knockdown on cell migration, which supports the hypothesis that Cyr61-medated FAK/AKT activation is involved in the regulation of cancer migration in AMOT-knockdown lung cancer.
In summary, this study provides compelling evidence that AMOT has a major role in tumor suppression in lung cancer. AMOT exerts its repressive function through its action as an inhibitory partner of oncogenic YAP/TAZ signaling. Restricting YAP/TAZ in the cytoplasm decreases Cyr61 expression, which reduces the metastatic phenotypes of tumor cells. Taken together, this study delineates the functional role of AMOT in lung cancer progression. AMOT expression in lung cancer specimens may be a valuable prognostic biomarker, and further investigations on AMOT functions may provide a potential treatment strategy for lung cancer.
MATERIALS AND METHODS

Cell cultures
The less invasive (CL1-0) and highly invasive (CL1-5) human lung adenocarcinoma cell lines were provided by Dr Pan-Chyr Yang (Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco BRL (Grand Island, NY, USA), AMOT-knockdown LLC-1 and CL1-0 cells were transplanted into C57BL/6 (for LLC-1 cells) or BALB/c athymic nude mice (for AMOT-knockdown CL1-0 cells) by subcutaneous injection. Tumor volume was measured using a caliper and recorded (for CL1-0 cells) every day. For metastasis experiment, AMOT-knockdown LLC-1 cells were delivered into mice by tail vein injection. Mice were killed at 22 days after injection, and tumor nodules on the surface of lungs were counted. Tumor sections were subjected to Ki-67 or YAP/TAZ and histological staining. Tumor cells with positive Ki-67 nuclear staining were counted and normalized to total tumor in a field. *Significant difference with the controls, by the Student's t-test (P o0.05).
Life Technologies (Grand Island, NY, USA)). 25, 26 The mouse LLC (CLR1642) cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum plus 1% antibiotics.
Microarray
Microarray experimental procedures were performed following the manufacturer's protocols. Total RNA (1 μg) was amplified by an Agilent Quick Amp Labeling Kit (Agilent Technologies, Santa Clara, CA, USA). LLC-5 cells were labeled with Cy5, and LLC-1 cells were labeled with Cy3 in an in vitro transcription process. Cy-labeled cRNA (0.825 μg) was cleaved to an average size of about 50-100 nucleotides by incubation with fragmentation buffer (Agilent Technologies) at 60°C for 30 min. An equal amount of Cy-labeled cRNA was pooled and hybridized to an Agilent SurePrint G3 Mouse GE 8 × 60 K microarray (Agilent Technologies) at 65°C for 17 h.
After washing and drying by nitrogen gun blowing, the microarrays were scanned by an Agilent microarray scanner (Agilent Technologies) at 535 nm for Cy3 and 625 nm for Cy5. The scanned images were analyzed by the Feature Extraction Software 10.5 (Agilent Technologies), an image analysis and normalization software used to quantify signal and background intensity for each feature. The data were then substantially normalized by the rank-consistency-filtering LOWESS method.
Gene knockdown and overexpression
Knockdown of AMOT in CL1-0 and YAP/TAZ in CL1-5 was performed using a lentiviral expression system provided by the National RNAi Core Facility (Taipei, Taiwan). The lentiviruses were produced by co-transfecting HEK293T with pLKO-AS2, pLKO-AS3-AMOT-1 and two packaging plasmids (pCMVVDR8.91 and pMD.G). The stable clones were established by puromycin selection. The efficacy of the AMOT shRNA plasmid was assessed by qRT-PCR. Knockdown of YAP, TAZ and Cyr61 was performed by ON-TARGET plus siRNA reagents transfection (Dharmacon, Chicago, IL, USA).
For AMOT (p130) overexpression, cells were transfected with pCMV or pCMV-AMOT (p130) plasmid (Origene, Rockville, MD, USA).The stable clones were established by treatment with G418.
For mouse AMOT inhibition, LLC cells were transfected with either control or AMOT shRNA plasmid provided by the National RNAi Core Facility. The efficacy of siRNA was assessed by qRT-PCR.
Cell proliferation, migration and invasion
Cell proliferation was determined by BrdU incorporation, which was performed using a BrdU Cell Proliferation Assay kit (Millipore Corp., Bedford, MA, USA). Cell migration was assessed by scratch wound-healing assay. The cells were allowed to grow into full confluence in 24-well plates. The following day, a uniform scratch was made down the center of the well using a micropipette tip, followed by washing once with phosphatebuffered saline. Photographic imaging was performed using an Olympus 1 × 50 inverted microscope (Olympus, Tokyo, Japan). Cell migration and invasion were also assessed by QCM 24-well Cell Migration Assay and Invasion Systems (Millipore), according to the manufacturer's instructions.
Immunoblot/immunoprecipitation
The cells were lysed on ice for 15 min in M-PER solution. The cell lysate was centrifuged at 14 000 g for 15 min, and the supernatant fraction was collected for immunoblotting. Equivalent amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10-12%) and transferred to polyvinylidene difluoride membranes. After blocking for 1 h in 5% non-fat dry milk in Tris-buffered saline, the membranes were incubated with the desired primary antibody for 1-16 h. The membranes were then treated with the appropriate peroxidaseconjugated secondary antibody and the immunoreactive proteins were detected using an enhanced chemiluminescence kit (Millipore) according to the manufacturer's instructions.
The primary antibodies used to target YAP/TAZ, N-cadherin, E-cadherin, snail, vimentin, FAK (total and phosphorylated forms), AKT (total and phosphorylated forms) and tubulin were from Cell Signaling Technology (Danvers, MA, USA), whereas AMOT, YAP and TAZ antibodies were from Abcam Ltd, (Cambridge, UK). Actin antibodies and anti-glyceraldehyde-3phosphate dehydrogenase (GAPDH) were from Millipore. Anti-LaminA/C antibody was from BD Biosciences (Allschwil, Switzerland).
For immunoprecipitation, cell lysates (200 μg of total protein) were incubated with 2 μg of anti-YAP/TAZ overnight and then with 20 μl of protein A-agarose beads (Millipore) for 2 h at 4°C. YAP and AMOT were detected by incubating the blots with specific antibodies.
Quantitative real-time PCR
RNA isolation was performed using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was prepared using an oligo (dT) primer and reverse transcriptase (Takara, Shiga, Japan) following the standard protocols. RT-PCR was performed using SYBR Green on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Each PCR reaction mixture contained 200 nM of each primer, 10 μl of 2 × SYBR Green PCR Master Mix (Applied Biosystems), 5 μl cDNA and RNase-free water for a total volume of 20 μl. The PCR reaction was performed with a denaturation step at 95°C for 10 min and then 40 cycles at 95°C for 15 s and 60°C for 1 min. All PCRs were performed in triplicate and normalized to the internal control GAPDH mRNA. Relative expression levels were presented using the 2 -ΔΔCT method. The AMOT level in Lung Cancer cDNA Array I (Origene) was also measured by PCR.
Immunofluorescence
Non-cancer and cancer lung tissue specimens obtained from human lung cancer patients were embedded in optimal cutting temperature and frozen in liquid nitrogen. Sections (3-5 μm) were fixed with acetone at − 20°C and stained with AMOT antibody (Abcam) or co-stained by anti-YAP/TAZ antibody (Cell Signaling Technology). After washing with phosphate-buffered saline containing 0.1% Tween-20, the slides were incubated with Dylight 488-or Dylight 549-conjugated secondary antibodies (Rockland, Gilbertsville, PA, USA), with or without DAPI (4,6diamidino-2-phenylindole), for 1 h at room temperature.
Spectral image acquisition was performed using a Zeiss LSM 700 confocal microscope and quantitated by the Zen 2011 software (Carl Zeiss MicroImaging LLC, Thornwood, NY, USA). Representative pixels from each of these images were selected, creating the emission spectra of each component. These spectra were then used to linearly unmix the images using the same setting in the Zen software. Two representative regions of interest (defined as areas with robust immunostaining,~100 μm 2 each) per slide were chosen, and the cumulative florescence intensity specific for Dyligh 488 (green) was determined. 52 Animal model/immunohistochemical reactions The LLC cells were transplanted into C57BL/6 mice by tail vein injection. The animals were then killed on day 20 after LLC transplantation, and the LLC cells in the lungs were isolated by mincing, collagenase type I digestion and filtering. LLC cells were cultured in a growth medium containing 10% fetal bovine serum and 1% penicillin-streptomycin and expanded for second-round transplantation. The sub-line of the first-round transplantation was designated as LLC-1 and sub-lines from 2, 3, 4 and 5 rounds of transplantation were designated as LLC-2, -3, -4 and -5, respectively.
The LLC-1, AMOT-knockdown LLC-1, CL1-0, and AMOT-knockdown CL1-0 cells were transplanted into C57BL/6 or nude mice by subcutaneous injection or tail vein injection. After transplantation, tumor size was measured using calipers, while tumor volume was estimated using the formula:
Tumor volume mm 3 À Á ¼ long diameter short diameter 2 À Á =2
The animals were killed on day 24, and the number of tumor nodules was recorded for analysis of the incidence of lung cancer. The tumor samples were fixed in 10% buffered formalin, dehydrated and embedded in paraffin blocks from which hematoxylin and eosin-stained slides were made and used for verification of the histopathological diagnosis. All immunohistochemical reactions were performed on 5-μm-thick paraffin sections. Briefly, the sections were de-paraffinized in xylene and rehydrated and then incubated in target retrieval solution (DAKO, Glostrup, Denmark) in an autoclave for 8 min to retrieve the antigens. The activity of endogenous peroxidase was blocked by incubation with 3% H 2 O 2 for 10 min.
The YAP/TAZ and Ki-67 antigen expression levels were demonstrated using the mouse monoclonal anti-YAP/TAZ (dilution 1:100) and anti-Ki-67 (dilution 1:100) antibodies, respectively. The sections were incubated with primary antibodies overnight at 4°C. The studied antigens were then visualized using biotinylated antibodies and streptavidin-conjugated with horseradish peroxidase. Diaminobenzidine (DakoCytomation, Glostrup, Denmark) served as the substrate, and all of the sections were counterstained with hematoxylin.
Statistical analysis
Data were expressed as means ± s.d., and statistical comparisons were made using analysis of variance. Significant differences (Po 0.05) between the means of the two test groups were analyzed by the Student's t-test.
